72 results about "Propionine" patented technology

The present invention relates to the manufacture of the compounds of formula (I) said compounds of formula (I) being valuable intermediates in the manufacture of Dolastatin 10 analogues, which are useful in the treatment of cancer.

The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the solution has a pH of less than about 7.8, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and / or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, and wherein the molar ratio of arginine to ibuprofen is selected to achieve a pH of less than about 7.8.

A method of repelling wasps, which method comprises using a preparation comprising (a) one or more of ethyl 3-(N-n-butyl-N-acetylamino)propionate, dihydronepetalactone, and extract of catmint, and (b) at least one compound selected from certain perfume ingredients. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

The invention provides a novel 2-(2-fluorine-4biphenyl)-propionic acid pharmaceutical composition. Flurbiprofen and basic amino acid arginine or lysine form a pharmaceutical composition solution. The composition can be administrated in an injection or oral administration manner and can also be further administrated in a freeze-drying manner. Compared with a flurbiprofen axetil injection, a flurbiprofen composition not only does not influence the antipyretic, anti-inflammation and analgestic effects of the flurbiprofen, but also has the advantages of simple technology, low cost, high quality, stable long shelf life and convenience in quality control, storage and transportation; moreover, compared with a conventional oral preparation, the flurbiprofen composition has the same low gastrointestinal tract adverse reaction as the flurbiprofen axetil injection.

The invention concerns an in vitro method for determining if an individual is infected by a bacterium of the Propionibacterium genus comprising: (i) detecting antibodies directed against at least one protein of sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, in a biological sample of the individual, and (ii) deducing therefrom that the individual is infected by a bacterium of the Propionibacterium genus. The invention further concerns the kit for diagnosing of such an infection.

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

The present invention relates to the field of biotechnology, particularly to special primers for identification or assisted identification of Propionibacterium acnes, and applications thereof, wherein the primers are a primer pair formed by combining any two sequences selected from sequences represented in SEQ ID NO:1-6. According to the present invention, the special primers provide great significance for the species identification of the Propionibacterium acnes and the prevention and control of facial diseases caused by the Propionibacterium acnes infection.

The invention discloses a method for purifying propionibacterium strain plasmid. By performing pretreatment and subsequent treatment on thallus, high-purity plasmid can be obtained from a propionibacterium strain. Compared with the conventional method, the method has the advantages of greatly improving the concentration and the purity of the plasmid. The method lays a solid foundation for research in the aspect of molecular operation of propionibacterium and possibly has universal application significance to other gram-positive bacteria (such as lactic acid bacteria).

A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.

The invention discloses an improved production technology of a clobetasol propionate intermediate (betamethasone-17-propionate). Two steps namely cyclo-esterification and hydrolysis in the conventional technology are merged into one step. By merging the steps, the procedure and production period are shortened, the product purity and yield are increased, the energy consumption is reduced, the raw materials and auxiliary materials are saved; the environment pollution is reduced, and the production cost is reduced.

The invention relates to a system for preparing propionate through ethylene carbonylation. The system comprises a separating and refining unit and a bubbling reactor (R1) coupled with the separating and refining unit, a gas-phase reaction raw material (G1) and a liquid-phase reaction raw material (L1) for preparing the propionate product (L6) are subjected to a carbonylation reaction in a bubbling reactor (R1), and a generated propionate-containing material (L2) is separated and purified by a separating and refining unit to prepare the propionate product (L6). Compared with the prior art, through the bubbling reactor, gas-liquid two-phase contact is more sufficient, the gas-liquid two-phase reaction rate is increased, and the raw material conversion rate is increased; the content of the deactivated catalyst in the material returned to the reactor is reduced through the membrane-based solid-liquid separator, the enrichment and regeneration of the deactivated catalyst can be realized, and the utilization rate of the catalyst is also improved.

The invention discloses two methods of preparing a dabigatran etexilate intermediate 3-[N-(2-pyridyl)-3-amino-4-methylamino benzamido]-ethyl propionate (I).

The present invention relates to an improved process for the preparation of substituted Fluticasone derivatives. The invention also reveals the processes for the purification of Fluticasones and related intermediates to provide the highly pure product.

The invention discloses medical application of gigantol and a drug for resisting propionibacterium acnes. The gigantol is applied to preparation of the drug for resisting the propionibacterium acnes,has no toxic and side effects to human bodies, can be used as the drug for resisting the propionibacterium acnes to replace conventional antibiotic drugs which cause relapse and infections easily andis prone to produce drug resistance in some aspects and becomes the first choice clinically, and has great application prospects.

The invention relates to a 4-substituted-4-(N-propionyl) aniline piperidine compound and a preparation method and application thereof. The structure of the compound is shown in Formula (I) or hydrochloride thereof, wherein R1 is a substituent with a mother nucleus structure of propofol, and R2 is 3-methyl propionate group or a benzyl group. The compound can be dissolved in water, and can achieve analgesic and sedative effects simultaneously. Thus, the compound is applicable to analgesia and sedation of patients needing postoperative care, and is particularly conducive to operation of the automatic dosing system by patients, and the operations by anesthesia doctors can be reduced. According to the basic preparation method, the compound is prepared via condensation of propofol (III) and a 4-formyl-4-(N-phenyl propoxy amide)-N-substituted piperidine compound (II).

The invention discloses a recombinant bacterium. The recombinant bacterium is used for expressing 2-ketoisovalerate deacidification enzyme (also called ketoacid decarboxylase). The recombinant bacterium is obtained by modifying a genome of a recipient bacterium, wherein the modification comprises the step of enabling the recipient bacterium to express the 2-ketoisovalerate deacidification enzyme, and the recipient bacterium is pseudomonas or escherichia coli. The method for synthesizing the propionic acid by using the recombinant bacterium is characterized in that the propionic acid is synthesized from 2-ketobutyric acid under the catalysis of 2-ketoisovalerate deacidilase. A novel metabolic pathway for synthesis of propionic acid is provided. The transformation rate of propionic acid is 96.67% when the recombinant pseudomonas PS32 obtained after transformation in the invention is used for catalyzing threonine synthesis for 24 hours; and after material supplementation, the conversion rate of the propionic acid can be 98.47% during catalysis of threonine synthesis by the PS32. The recombinant escherichia coli obtained after transformation in the invention can be used for transforming L-threonine with a concentration of 400 mM into propionate with a concentration of 393 mM within 24 hours, and a conversion rate is 98.25%.

Disclosed is a process for producing a thiabenzoazulene-propionic acid derivative which is useful as an active ingredient of an antihistaminic agent or the like. According to the producing process of the present invention, it is possible to produce a thiabenzoazulene-propionic acid derivative where the 2-position of the thiabenzoazulene skeleton is substituted with propionic acid. The thiabenzoazulene propionic-acid derivative thus synthesized has excellent antagonistic action to histamine H1 receptor and low intracerebral transmigration and, therefore, is useful as an active ingredient of the pharmaceutical composition such as an antihistaminic agent.

The present invention discloses an application of sophorolipid in preparation of a medicine for preventing against propionibacterium acnes and a biofilm thereof. The sophorolipid is prepared from Wickerhamiella domercqiae var. sophorollipid CGMCC No.1576 through a fermentation method; a concentration of the sophorolipid in effectively inhibiting propionibacterium acnes is 0.12-1.5 g / L and a concentration of the sophorolipid in effectively inhibiting propionibacterium acnes biofilm is 2.0-2.5 g / L. Experiments confirm that the sophorolipid has a significant bacteriostatic effect, does not have any toxic and side effects on human body, can be used to replace a conventional antibiotic medicine that is prone to enable people to relapse and infect and have drug resistance after therapy in certain aspects, and has great application prospects.

The invention discloses a 2-(3-isoquinolinyl)-ethyl propionate derivative and a synthesis method thereof. According to the invention, O-acetyloxime with characteristics of easy preparation, structuraldiversity and multiple reaction centers is used as a raw material, the ortho-position C-H bond of the aromatic ring in the O-acetyloxime is activated under the action of a rhodium salt, a coupling reaction with allenoate is carried out, a series of 2-(3-isoquinolinyl)-ethyl propionate derivatives with different structures are synthesized, and the product can be further converted into a functionalproduct.; and the method has the advantages of easily available raw materials, simple operation, mild reaction conditions, diverse functional groups, and no need of pre-functionalization.

The invention provides a method for detecting beclomethasone propionate related substances. The method optimizes the separation degree of an impurity D and a main peak of beclomethasone propionate through liquid chromatography, and detects the main metabolite (impurity H), and is beneficial to the quality control of beclomethasone propionate and the improvement of dosing accuracy.

The invention provides application of imidazole propionic acid as a biomarker in preparation of a kit for predicting diabetic nephropathy and a related detection kit. The biomarker can be effectively used as an early diagnosis marker for predicting diabetic nephropathy, and has the advantages of accuracy, early stage and high precision.